Efficacy and Safety of Savolitinib Plus Osimertinib in EGFR-Mutant, MET-Aberrant Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Sep 2026· American Journal of Clinical Oncology· 0 citations· 31 references
Medicine
TL;DR
Combined therapy shows encouraging results in selected MET, post-TKI NSCLC, however, reliance on single-arm data warrants further randomized controlled trials.
Abstract
Objectives
NSCLC is the leading cause of cancer-related mortality. While combined therapy including savolitinib and osimertinib appears promising, there exists a lack of comprehensive pooled evidence regarding its anti-oncological activity.
The objective of this study is to evaluate the efficacy and safety of combined therapy in patients with NSCLC.
Methods
A comprehensive literature search was conducted in MEDLINE, the Cochrane Central Register of controlled trials, and ClinicalTrials.gov. Randomized controlled trials and prospective single-arm studies evaluating savolitinib combined with osimertinib were included. A random-effects single-arm meta-analysis of proportions was performed using logit transformation and inverse variance weighting, with restricted maximum likelihood (REML) estimation and Knapp-Hartung adjustment. Results were reported with a 95% CI, and heterogeneity was assessed using the I2 statistic. Sensitivity analysis was conducted using the Freeman-Tukey transformation.
Results
The primary analysis included 4 post-TKI, MET-selected combination cohorts (SACHI, SAVANNAH, and TATTON Part B; n=338) from 7 reports of 5 trials after de-duplication of overlapping data sets. First-line (FLOWERS) and MET-unselected (Yoh) cohorts were analyzed separately. The pooled objective response rate (ORR) was 53.9% (95% CI: 45.1-62.4), disease control rate (DCR) was 85.2% (79.2-89.8), 6-month progression-free survival (PFS) rate was 59.8%, and grade ≥3 adverse events occurred in 48.8% of patients. ORR estimates were consistent across studies and remained robust across sensitivity and subgroup analyses.
Conclusions
Combined therapy shows encouraging results in selected MET, post-TKI NSCLC. However, reliance on single-arm data warrants further randomized controlled trials.
This meta-analysis did not demonstrate a statistically significant OS and PFS benefit from veliparib plus temozolomide compared with control therapy, and future studies should focus on biomarker-driven approaches and optimized dosing strategies to better define the clinical utility of this regimen.
Parsa Sepehri, F. Hejazi, Milad Ghanikolahloo et al.· American Journal of Clinical...· 0 citations
OBJECTIVES
Sacituzumab govitecan (SG), a Trop-2-directed antibody-drug conjugate delivering SN-38, has shown promising activity in advanced breast cancer. However, variability across trials and inclusion of nonrandomized data in prior meta-analyses limit the certainty of its efficacy and safety. This study aimed to eva...
M. Amjad, M. Rafique, S. F. Hussain et al.· American Journal of Clinical...· 0 citations
Background Comparative evidence regarding the efficacy and safety of almonertinib in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) remains fragmented across randomized and real-world studies. We conducted a systematic review and meta-analysis to comprehensively evaluate the comparat...
Biao-Xue Rong, Hui Pan, T. Fu et al.· Frontiers in Pharmacology· 0 citations
Objective This study aimed to synthesize evidence from recent randomized controlled trials (RCTs) evaluating the efficacy of regorafenib, fruquintinib, and TAS-102 in patients with metastatic colorectal cancer (mCRC). Using a network meta-analysis, we compared long-term survival outcomes (overall and progression-free s...
Ying-Yu Zhou, Shi-Qing Zhao, Xiao-Yi Zheng et al.· Frontiers in Oncology· 0 citations
BackgroundMetastatic castration-resistant prostate cancer (mCRPC) remains driven by persistent androgen receptor signaling. Although enzalutamide (ENZ) is widely used, the incremental benefit of adding other agents remains uncertain. We evaluated the efficacy and safety of specific pharmacologic agents added to ENZ in...
Yeison Cruz Castillo, Alejandro Chen Liang, Victor M. Samperio et al.· Journal of Oncology Pharmacy...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.